Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations
AbstractThe use of integrase inhibitors (INI) is increasing in antiretroviral therapies (ART) and INI are not all equal regarding genetic barrier to resistance. The aim of this manuscript was to review main in vivo and in vitro knowledge about two particular integrase resistance-associated mutations: R263K and E157Q. The R263K mutation was the first mutation rarely found selected at time of virological failure in patients failing a first-line dolutegravir-based treatment. Further in vitro studies on R263K mutants showed a moderate increase in phenotypic resistance level and a drastic reduction in viral replicative capacity. No compensatory mutations were evidenced. The E157Q mutation is polymorphic, found between 1.7% and 5.6% of viral sequences issued from ART-naïve patients depending on the viral subtype; as well as acquired resistance emerging at failure of a raltegravir-based regimen in two case reports. We reported data on phenotypic resistance level of E157Q mutants and virological response of patients harboring a E157Q virus initiating an INI-based regimen, showing that dolutegravir might be the most recommended INI in such patients. These findings show that there is still a need for a better understanding of resistance mechanisms to INI and emphasized the importance of genotypic background in viral evolution under drug pressure. View Full-Text
Share & Cite This Article
Charpentier, C.; Descamps, D. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations. Viruses 2018, 10, 41.
Charpentier C, Descamps D. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations. Viruses. 2018; 10(1):41.Chicago/Turabian Style
Charpentier, Charlotte; Descamps, Diane. 2018. "Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations." Viruses 10, no. 1: 41.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.